Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D07EFO
|
|||
Former ID |
DNC002309
|
|||
Drug Name |
ISIS 113902
|
|||
Drug Type |
Antisense drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Company |
Isis Pharmaceuticals
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | MEKK2 messenger RNA (MAP3K2 mRNA) | Target Info | . | [1] |
KEGG Pathway | MAPK signaling pathway | |||
Gap junction | ||||
GnRH signaling pathway | ||||
NetPath Pathway | IL5 Signaling Pathway | |||
TGF_beta_Receptor Signaling Pathway | ||||
TCR Signaling Pathway | ||||
Panther Pathway | B cell activation | |||
EGF receptor signaling pathway | ||||
FGF signaling pathway | ||||
Pathway Interaction Database | ErbB1 downstream signaling | |||
Trk receptor signaling mediated by the MAPK pathway | ||||
WikiPathways | Insulin Signaling | |||
EGF/EGFR Signaling Pathway | ||||
MAPK Cascade | ||||
MAPK Signaling Pathway | ||||
BDNF signaling pathway | ||||
IL-1 signaling pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.